Prediction of tacrolimus blood concentration by CYP3A5 gene polymorphism

Prediction of tacrolimus blood concentration by CYP3A5 gene polymorphism - Prediction of tacrolimus blood concentration by CYP3A5 gene polymorphism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000057127

Enrollment

200

Registered

2025-06-01

Start date

2025-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients taking tacrolimus or who are planning to take it for kidney transplant etc.

Interventions

Evaluate CYP3A5 genetic polymorphisms Measure blood and urinary concentrations of tacrolimus and metabolites periodically up to 24 hours after dosing.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients currently taking tacrolimus or who are planning to take tacrolimus

Exclusion criteria

Exclusion criteria: non

Design outcomes

Primary

Measure	Time frame
Predicting tacrolimus blood concentrations according to CYP3A5 gene polymorphisms	—

Countries

Japan

Contacts

Public ContactKENGO FURUICHI

Kanazawa Medical University Department of Nephrology

furuichi@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026